The essential role of infection-detection technologies for malaria elimination and eradication.

Recent emphasis on malaria elimination and eradication (E&E) goals is changing the way that experts evaluate malaria diagnostic tools and tactics. As prevalence declines, the focus of malaria management is pivoting toward low-density, subclinical infections and geographically and demographically concentrated reservoirs. These and other changes present challenges and opportunities for innovations in malaria diagnostics aimed at meeting the needs of malaria elimination programs. Developing such technologies requires a review of the operational approaches to detecting malaria infections in areas of declining prevalence. Here we review recent research on epidemiology and biology related to malaria elimination and operational factors that influence E&E strategies. We further propose use-scenarios and a target product profile framework to define and prioritize the required attributes of infection-detection technologies.

Concurrent trastuzumab and HER2/neu-specific vaccination in patients with metastatic breast cancer.

PURPOSE: The primary objectives of this phase I/II study were to evaluate the safety and immunogenicity of combination therapy consisting of concurrent trastuzumab and human epidermal growth factor receptor 2 (HER2)/neu-specific vaccination in patients with HER2/neu-overexpressing metastatic breast cancer. PATIENTS AND METHODS: Twenty-two patients with stage IV HER2/neu-positive breast cancer receiving trastuzumab therapy were vaccinated with an HER2/neu T-helper peptide-based vaccine. Toxicity was graded according to National Cancer Institute criteria, and antigen specific T-cell immunity was assessed by interferon gamma enzyme-linked immunosorbent spot assay. Data on progression-free and overall survival were collected. RESULTS: Concurrent trastuzumab and HER2/neu vaccinations were well tolerated, with 15% of patients experiencing an asymptomatic decline in left ventricular ejection fraction below the normal range during combination therapy. Although many patients had pre-existing immunity specific for HER2/neu and other breast cancer antigens while treated with trastuzumab alone, that immunity could be significantly boosted and maintained with vaccination. Epitope spreading within HER2/neu and to additional tumor-related proteins was stimulated by immunization, and the magnitude of the T-cell response generated was significantly inversely correlated with serum transforming growth factor beta levels. At a median follow-up of 36 months from the first vaccine, the median overall survival in the study population has not been reached. CONCLUSION: Combination therapy with trastuzumab and a HER2/neu vaccine is associated with minimal toxicity and results in prolonged, robust, antigen-specific immune responses in treated patients.